Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 8/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9152668 | 0.87 | TTR (0.41) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12200891 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL13609012 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL9288054 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL9287368 | 0.82 | CA2 (0.54) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12603022 | 0.82 | CA2 (0.65) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12832696 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL13274117 | 0.82 | CYP1A2 (0.71) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL1645476 | 0.81 | CA2 (0.52) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL9674671 | 0.81 | CA2 (0.63) | CYP1A2CYP2C19HTTHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242957-B2 | Thiophene-2-carboximidamide based selective neuronal nitric oxide inhibitors | NORTHWESTERN UNIVERSITY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140256958-A1 | Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389506-B2 | Compounds for therapy and diagnosis | PRANA BIOTECHNOLOGY LTD. (AU) | 2013-03-05 | — | — | US | disclosed |
| US-20120270919-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227503-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110172285-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110110850-A1 | COMPOUNDS FOR THERAPY AND DIAGNOSIS | PRANA BIOTECHNOLOGY LTD. (AU) | 2011-05-12 | — | — | US | disclosed |
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270919-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | CYP1A2 3507/4885CYP2C19 3954/4885HTT 2323/4885 |
| US-20110110850-A1 | COMPOUNDS FOR THERAPY AND DIAGNOSIS | APP, PSEN1, BACE1 | CYP1A2 1688/4885CYP2C19 2104/4885HTT 16/4885 |
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | CYP1A2 3507/4885CYP2C19 3954/4885HTT 2323/4885 |
| US-20110172285-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | CYP1A2 3507/4885CYP2C19 3954/4885HTT 2323/4885 |
| US-20140256958-A1 | Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors | NOS2, NOS1, NOS3 | CYP1A2 152/4885CYP2C19 359/4885HTT 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.